|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
EP2185188B1
(en)
|
2007-08-22 |
2014-08-06 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
|
|
AU2008312457B2
(en)
|
2007-10-19 |
2014-04-17 |
Genentech, Inc. |
Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
|
|
TR201809128T4
(tr)
|
2009-07-15 |
2018-07-23 |
Aimm Therapeutics Bv |
Gram-pozitif bakterilere spesifik bağlanan bileşikler.
|
|
RU2016105962A
(ru)
*
|
2009-12-04 |
2018-11-23 |
Дженентек, Инк. |
Мультиспецифические антитела, аналоги антител, композиции и способы
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
|
WO2011118739A1
(ja)
*
|
2010-03-26 |
2011-09-29 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
|
WO2011130598A1
(en)
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
SG185428A1
(en)
|
2010-06-08 |
2012-12-28 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
|
WO2012074757A1
(en)
|
2010-11-17 |
2012-06-07 |
Genentech, Inc. |
Alaninyl maytansinol antibody conjugates
|
|
CA2837840C
(en)
|
2011-06-10 |
2020-08-04 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
PT2750713E
(pt)
|
2011-10-14 |
2016-01-20 |
Genentech Inc |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
US20150030602A1
(en)
*
|
2011-12-23 |
2015-01-29 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
|
BR112014020697B1
(pt)
*
|
2012-02-24 |
2024-01-09 |
Alteogen Inc |
Anticorpo modificado compreendendo um motivo contendo cisteína na terminação do anticorpo, conjugado anticorpo-droga modificado compreendendo uma droga ligada ao anticorpo modificado e método de produção do mesmo
|
|
KR20140135251A
(ko)
|
2012-03-16 |
2014-11-25 |
코바겐 아게 |
항종양 활성이 있는 신규 결합 분자
|
|
EP2638916A1
(en)
*
|
2012-03-16 |
2013-09-18 |
Covagen AG |
Novel binding molecules with antitumoral activity
|
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
|
JP6498600B2
(ja)
|
2012-06-08 |
2019-04-10 |
ストロ バイオファーマ インコーポレーテッド |
部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
|
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
KR102006997B1
(ko)
*
|
2012-07-03 |
2019-08-02 |
한국생명공학연구원 |
ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자
|
|
DK2890402T3
(da)
|
2012-08-31 |
2019-07-15 |
Sutro Biopharma Inc |
Modificerede aminosyrer omfattende en azidogruppe
|
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
EP2906296B1
(en)
|
2012-10-12 |
2018-03-21 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
BR112015008251B1
(pt)
|
2012-10-12 |
2023-09-26 |
Medimmune Limited |
Pirrolobenzodiazepinas, conjugados destas, composição e composição farmacêutica compreendendo os conjugados, uso dos conjugados para o tratamento de uma doença proliferativa e método para preparar os conjugados
|
|
WO2014057114A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
ES2738310T3
(es)
|
2012-10-12 |
2020-01-21 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
WO2014057120A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US9931414B2
(en)
|
2012-10-12 |
2018-04-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
NZ707486A
(en)
|
2012-10-12 |
2018-09-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine - anti-psma antibody conjugates
|
|
ES2649990T3
(es)
|
2012-10-12 |
2018-01-16 |
Medimmune Limited |
Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
|
|
US9745303B2
(en)
|
2012-10-12 |
2017-08-29 |
Medimmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
|
HK1216176A1
(zh)
|
2012-12-21 |
2016-10-21 |
Medlmmune Limited |
用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
|
BR112015014669B1
(pt)
|
2012-12-21 |
2023-09-26 |
Medimmune Limited |
Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
|
|
US20140187501A1
(en)
*
|
2012-12-28 |
2014-07-03 |
Blend Therapeutics, Inc. |
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
|
|
CN103933575B
(zh)
|
2013-01-23 |
2017-09-29 |
上海新理念生物医药科技有限公司 |
一种三齿型连接子及其应用
|
|
CA2900755C
(en)
|
2013-02-08 |
2021-07-20 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
MX2015010682A
(es)
|
2013-02-22 |
2016-05-31 |
Stemcentrx Inc |
Nuevos conjugados de anticuerpos y usos de los mismos.
|
|
RU2711935C2
(ru)
|
2013-03-11 |
2020-01-23 |
Джензим Корпорейшн |
Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
CN105142674B
(zh)
|
2013-03-13 |
2018-11-13 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓和其结合物
|
|
AU2014244245C1
(en)
|
2013-03-13 |
2018-04-19 |
Genentech, Inc. |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AR095863A1
(es)
*
|
2013-04-16 |
2015-11-18 |
Genentech Inc |
Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
|
|
BR112015029754A2
(pt)
|
2013-05-31 |
2017-09-26 |
Genentech Inc |
anticorpos anti-teicoico da parede e conjugados
|
|
US9803002B2
(en)
|
2013-05-31 |
2017-10-31 |
Genentench, Inc. |
Anti-wall teichoic antibodies and conjugates
|
|
MA38686A1
(fr)
|
2013-05-31 |
2017-10-31 |
Genentech Inc |
Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
|
|
EP3018143B1
(en)
|
2013-07-03 |
2019-05-29 |
Seoul National University R&DB Foundation |
Chicken antibody transformed into cysteine and site-specific conjugation using same
|
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
JP6993084B2
(ja)
|
2013-08-12 |
2022-02-03 |
ジェネンテック， インコーポレイテッド |
１－（クロロメチル）－２，３－ジヒドロ－１ｈ－ベンゾ［ｅ］インドール二量体抗体 － 薬物コンジュゲート化合物、並びに使用及び処置の方法
|
|
PE20160674A1
(es)
|
2013-08-28 |
2016-07-21 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
|
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
|
KR102572149B1
(ko)
|
2013-10-11 |
2023-08-30 |
아사나 바이오사이언시스 엘엘씨 |
단백질-폴리머-약물 접합체
|
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
KR102087850B1
(ko)
|
2013-10-11 |
2020-03-12 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-고분자-약물 접합체
|
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2928952A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
|
UA118113C2
(uk)
|
2013-12-16 |
2018-11-26 |
Дженентек, Інк. |
Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
|
|
EP3082876B1
(en)
|
2013-12-16 |
2018-01-17 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
|
WO2015127407A1
(en)
|
2014-02-21 |
2015-08-27 |
Stemcentrx, Inc. |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
CN104788566A
(zh)
*
|
2014-03-11 |
2015-07-22 |
南京任诺药业有限公司 |
用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-V280C
|
|
CN104672330A
(zh)
*
|
2014-03-11 |
2015-06-03 |
南京任诺药业有限公司 |
用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-N267C
|
|
PL3129067T3
(pl)
|
2014-03-19 |
2023-05-08 |
Genzyme Corporation |
Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
|
|
US10285955B2
(en)
|
2014-04-10 |
2019-05-14 |
Af Chemicals, Llc |
Affinity medicant conjugate
|
|
CN106458922A
(zh)
|
2014-04-10 |
2017-02-22 |
Af化学药品有限责任公司 |
亲和药物共轭物
|
|
US11135182B2
(en)
|
2014-04-10 |
2021-10-05 |
Af Chemicals, Llc |
Affinity medicant conjugates
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
KR20220018620A
(ko)
|
2014-04-25 |
2022-02-15 |
피에르 파브르 메디카먼트 |
Igf-1r 항체 및 암 치료를 위한 운반체를 어드레싱하는 그의 용도
|
|
EP3134124B1
(en)
|
2014-04-25 |
2019-02-20 |
Pierre Fabre Medicament |
Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
|
|
CN106470708B
(zh)
|
2014-04-25 |
2019-12-31 |
皮埃尔法布雷医药公司 |
抗体-药物-缀合物和其用于治疗癌症的用途
|
|
US10273208B2
(en)
*
|
2014-05-23 |
2019-04-30 |
Northwestern University |
Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
TW201625688A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
經半胱胺酸改造之抗體及接合物
|
|
US10149913B2
(en)
|
2014-09-12 |
2018-12-11 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
|
CN107124870A
(zh)
|
2014-09-17 |
2017-09-01 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
|
|
JP2017533887A
(ja)
|
2014-09-17 |
2017-11-16 |
ジェネンテック， インコーポレイテッド |
ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
|
|
SG10202002153PA
(en)
|
2014-10-09 |
2020-05-28 |
Genzyme Corp |
Glycoengineered antibody drug conjugates
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
EP3223854A1
(en)
|
2014-11-25 |
2017-10-04 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
MX2017007169A
(es)
|
2014-12-03 |
2018-05-02 |
Genentech Inc |
Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
|
|
JP6751393B2
(ja)
|
2014-12-03 |
2020-09-02 |
ジェネンテック， インコーポレイテッド |
抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用
|
|
KR20170086536A
(ko)
|
2014-12-03 |
2017-07-26 |
제넨테크, 인크. |
항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
|
|
WO2016164916A1
(en)
|
2015-04-10 |
2016-10-13 |
Thomas Jefferson University |
Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
|
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201514928D0
(en)
|
2015-08-21 |
2015-10-07 |
King S College London |
PDD compounds
|
|
HUE053614T2
(hu)
*
|
2015-09-22 |
2021-07-28 |
Byondis Bv |
T-DM1 refrakter rákos páciensek SYD985 kezelése
|
|
EP3365025B1
(en)
|
2015-10-20 |
2020-07-15 |
Genentech, Inc. |
Calicheamicin-antibody-drug conjugates and methods of use
|
|
US9669106B2
(en)
|
2015-10-26 |
2017-06-06 |
Pierre Fabre Medicament |
Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
|
|
US10858423B2
(en)
|
2015-10-26 |
2020-12-08 |
Pierre Fabre Medicament |
Composition for the treatment of IGF-1R expressing cancer
|
|
SG11201802769RA
(en)
|
2015-10-29 |
2018-05-30 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
CN107847605B
(zh)
|
2015-11-25 |
2021-12-24 |
乐高化学生物科学股份有限公司 |
包含分支接头的抗体-药物缀合物及其相关方法
|
|
US10689458B2
(en)
|
2015-11-30 |
2020-06-23 |
Pfizer Inc. |
Site specific HER2 antibody drug conjugates
|
|
MX2018007451A
(es)
*
|
2015-12-18 |
2018-11-09 |
Eisai R&D Man Co Ltd |
Inmunoglobulinas conjugadas con lisina c-terminal.
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
MX2018009085A
(es)
|
2016-01-27 |
2019-05-09 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
MA45280B1
(fr)
*
|
2016-03-02 |
2021-08-31 |
Eisai R&D Man Co Ltd |
Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
|
|
CN108713020A
(zh)
|
2016-03-04 |
2018-10-26 |
豪夫迈·罗氏有限公司 |
制备抗体-利福霉素缀合物的方法
|
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CN118436801A
(zh)
|
2016-05-20 |
2024-08-06 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック， インコーポレイテッド |
部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
|
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
|
CN118846112A
(zh)
*
|
2016-10-08 |
2024-10-29 |
四川百利药业有限责任公司 |
半胱氨酸改造的抗体-毒素偶联物及其制备方法
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
CN110300601B
(zh)
|
2017-02-08 |
2024-01-05 |
Adc治疗有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US11160872B2
(en)
|
2017-02-08 |
2021-11-02 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
KR101938800B1
(ko)
|
2017-03-29 |
2019-04-10 |
주식회사 레고켐 바이오사이언스 |
피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
|
|
AU2018250695A1
(en)
|
2017-04-14 |
2019-11-07 |
Kodiak Sciences Inc. |
Complement factor D antagonist antibodies and conjugates thereof
|
|
EP3612537B1
(en)
|
2017-04-18 |
2022-07-13 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
CN110536703B
(zh)
|
2017-04-20 |
2024-07-12 |
Adc治疗有限公司 |
使用抗axl抗体-药物缀合物的组合疗法
|
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
|
RS62928B1
(sr)
|
2017-08-18 |
2022-03-31 |
Medimmune Ltd |
Konjugati pirolobenzodiazepina
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
IL278480B1
(en)
|
2018-05-09 |
2026-04-01 |
Ligachem Biosciences Inc |
Compositions and methods related to anti-CD19 antibody drug conjugates
|
|
CR20200564A
(es)
*
|
2018-05-24 |
2021-06-21 |
Janssen Biotech Inc |
Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
CN113286617A
(zh)
|
2018-10-19 |
2021-08-20 |
免疫医疗有限公司 |
吡咯并苯并二氮杂䓬缀合物
|
|
WO2020079239A1
(en)
|
2018-10-19 |
2020-04-23 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
EP3667323B1
(en)
|
2018-12-11 |
2024-11-13 |
AF Chemical LLC |
Methods, compositions and devices for treating cancer with illudofulvenes
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
CN117679532A
(zh)
|
2019-02-15 |
2024-03-12 |
上海药明合联生物技术有限公司 |
用于制备具有改善的同质性的抗体-药物缀合物的方法
|
|
US12109273B2
(en)
|
2019-02-15 |
2024-10-08 |
Wuxi Xdc Singapore Private Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
KR102503143B1
(ko)
*
|
2019-03-06 |
2023-02-24 |
주식회사 레고켐 바이오사이언스 |
인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
ES2967878T3
(es)
|
2019-03-15 |
2024-05-06 |
Medimmune Ltd |
Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
|
|
CR20210541A
(es)
|
2019-03-29 |
2021-12-20 |
Medimmune Ltd |
Compuestos y conjugados de estos
|
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2020291014B2
(en)
|
2019-06-13 |
2025-06-05 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
CA3148694A1
(en)
|
2019-09-03 |
2021-03-11 |
Romas Kudirka |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
|
WO2021067242A1
(en)
|
2019-09-30 |
2021-04-08 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
KR20220088901A
(ko)
|
2019-10-25 |
2022-06-28 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
티에노아제핀 면역접합체, 및 이의 용도
|
|
US20240123081A1
(en)
|
2019-10-25 |
2024-04-18 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
|
US11591295B2
(en)
|
2019-11-25 |
2023-02-28 |
Af Chemicals Llc |
Affinity illudofulvene conjugates
|
|
CA3166732A1
(en)
|
2020-01-22 |
2021-07-29 |
Medimmune Limited |
Compounds and conjugates thereof
|
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
|
CA3176626A1
(en)
|
2020-05-08 |
2021-11-11 |
David Dornan |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
|
CN116234586A
(zh)
|
2020-08-13 |
2023-06-06 |
博尔特生物治疗药物有限公司 |
吡唑并氮呯免疫缀合物及其用途
|
|
EP4208259A2
(en)
|
2020-09-04 |
2023-07-12 |
NovaRock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
|
CA3193594A1
(en)
|
2020-09-11 |
2022-03-17 |
Medimmune Limited |
Therapeutic b7-h4 binding molecules
|
|
JP2024501453A
(ja)
|
2020-12-11 |
2024-01-12 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗ｃｅａイムノコンジュゲート、及びそれらの使用
|
|
JP2023552790A
(ja)
|
2020-12-11 |
2023-12-19 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗ｐｄ－ｌ１イムノコンジュゲート、及びそれらの使用
|
|
EP4259211A1
(en)
|
2020-12-11 |
2023-10-18 |
Bolt Biotherapeutics, Inc. |
Anti-her2 immunoconjugates, and uses thereof
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
US20240091370A1
(en)
|
2020-12-11 |
2024-03-21 |
Bolt Biotherapeutics, Inc. |
Anti-her2 immunoconjugates, and uses thereof
|
|
EP4046996A1
(en)
|
2021-02-19 |
2022-08-24 |
Universität Bielefeld |
Cryptophycin compounds and conjugates thereof
|
|
WO2022197945A1
(en)
|
2021-03-17 |
2022-09-22 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
CN117940168A
(zh)
|
2021-03-26 |
2024-04-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
|
|
TW202304520A
(zh)
|
2021-03-26 |
2023-02-01 |
美商博特生物治療公司 |
２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途
|
|
GB202105187D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
US20240238427A1
(en)
|
2021-04-14 |
2024-07-18 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CN118475372A
(zh)
|
2021-10-29 |
2024-08-09 |
博尔特生物治疗药物有限公司 |
具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途
|
|
WO2023083846A1
(en)
|
2021-11-10 |
2023-05-19 |
Astrazeneca Ab |
Antibody molecules and conjugates
|
|
WO2023088963A1
(en)
|
2021-11-19 |
2023-05-25 |
Adc Therapeutics Sa |
Anti-il-13ralpha2 conjugates
|
|
US20230201366A1
(en)
|
2021-11-19 |
2023-06-29 |
Adc Therapeutics Sa |
Anti-psma conjugates
|
|
CN114214341B
(zh)
*
|
2021-12-30 |
2023-12-26 |
山西大学 |
番茄SlSERAT1;1基因或其片段在植物发育过程中的应用
|
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
|
EP4230222A1
(en)
|
2022-02-17 |
2023-08-23 |
Oxsonics Limited |
Combination therapy with an anti-axl antibody-pbd conjugate and nanocups
|
|
US20250170258A1
(en)
|
2022-02-28 |
2025-05-29 |
Adc Therapeutics Sa |
Dosage regimen
|
|
AU2023229884A1
(en)
|
2022-03-09 |
2024-10-10 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
|
CN119234152A
(zh)
|
2022-03-11 |
2024-12-31 |
阿斯利康(瑞典)有限公司 |
用于抗FRα抗体-药物缀合物疗法的评分方法
|
|
KR20250002133A
(ko)
*
|
2022-04-29 |
2025-01-07 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
항체-약물 접합체, 이의 약학적 조성물 및 용도
|
|
IL317733A
(en)
|
2022-06-27 |
2025-02-01 |
Astrazeneca Ab |
Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
|
|
WO2024052684A1
(en)
|
2022-09-09 |
2024-03-14 |
MyricX Pharma Limited |
Antibody drug conjugate comprising nmt inhibitor and its use
|
|
US20240165257A1
(en)
|
2022-11-01 |
2024-05-23 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
|
KR20250135788A
(ko)
|
2022-12-14 |
2025-09-15 |
페온 테라퓨틱스 리미티드 |
세포독성 화합물
|
|
WO2024137619A1
(en)
|
2022-12-20 |
2024-06-27 |
Bolt Biotherapeutics, Inc. |
Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
|
|
EP4637833A2
(en)
|
2022-12-23 |
2025-10-29 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|
|
EP4410314A1
(en)
|
2023-02-02 |
2024-08-07 |
ADC Therapeutics SA |
Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor
|
|
CN120981252A
(zh)
|
2023-02-14 |
2025-11-18 |
博尔特生物治疗药物有限公司 |
氮杂-苯并氮杂䓬免疫缀合物及其用途
|
|
JP2026506049A
(ja)
|
2023-02-16 |
2026-02-20 |
アストラゼネカ・アクチエボラーグ |
治療用結合分子を用いた癌の治療のための併用療法
|
|
WO2024186626A1
(en)
|
2023-03-03 |
2024-09-12 |
Bolt Biotherapeutics, Inc. |
Aza-bicyclic sting agonist immunoconjugates, and uses thereof
|
|
KR20250152101A
(ko)
|
2023-03-13 |
2025-10-22 |
하이델베르크 파마 리서치 게엠베하 |
암 치료에의 사용을 위한 피하 투여 항체-약물 접합체
|
|
TW202506194A
(zh)
|
2023-04-28 |
2025-02-16 |
英商梅迪繆思有限公司 |
用於治療癌症的ｂ７－ｈ４治療性結合分子
|
|
WO2025083064A1
(en)
|
2023-10-17 |
2025-04-24 |
Adc Therapeutics Sa |
Anti-asct2 conjugates
|
|
WO2025083061A1
(en)
|
2023-10-17 |
2025-04-24 |
Adc Therapeutics Sa |
Anti-napi2b conjugates
|
|
WO2025083067A1
(en)
|
2023-10-17 |
2025-04-24 |
Adc Therapeutics Sa |
Anti-claudin-6 conjugates
|
|
EP4548936A1
(en)
*
|
2023-10-30 |
2025-05-07 |
BioNTech SE |
Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
|
|
WO2025109097A2
(en)
|
2023-11-24 |
2025-05-30 |
Heidelberg Pharma Research Gmbh |
Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
|
|
AU2024394903A1
(en)
|
2023-12-06 |
2026-04-02 |
Adc Therapeutics Sa |
Anti-psma antibody drug conjugates comprising exatecan
|
|
EP4566631A1
(en)
|
2023-12-06 |
2025-06-11 |
Heidelberg Pharma Research GmbH |
New antibody drug conjugate as well as methods of production and uses thereof
|
|
WO2025134068A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Antibody drug conjugates targeting proteinopathies, and uses thereof
|
|
GB202403391D0
(en)
|
2024-03-08 |
2024-04-24 |
Myricx Pharma Ltd |
Novel compounds and their use in therapy
|
|
GB202405758D0
(en)
|
2024-04-24 |
2024-06-05 |
King S College London |
Compounds
|
|
GB202407700D0
(en)
|
2024-05-30 |
2024-07-17 |
Francis Crick Institute Ltd |
F-actin binding agents
|
|
WO2026006688A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Degrader antibody conjugates and uses thereof
|
|
WO2026006689A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Bcl-xl degrader antibody conjugates and uses thereof
|
|
WO2026020031A2
(en)
|
2024-07-18 |
2026-01-22 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|
|
WO2026050213A1
(en)
|
2024-08-27 |
2026-03-05 |
Usbolt Biotherapeutics, Inc. |
Tlr agonist immunoconjugates and uses thereof
|
|
WO2026055185A1
(en)
|
2024-09-04 |
2026-03-12 |
Bolt Biotherapeutics, Inc. |
Sting agonist immunoconjugates and uses thereof
|
|
EP4706676A1
(en)
*
|
2024-09-10 |
2026-03-11 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Cysteine-engineered antigen-binding domains
|
|
EP4706675A1
(en)
*
|
2024-09-10 |
2026-03-11 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Cysteine-engineered chimeric antigen receptor
|
|
WO2026057740A1
(en)
|
2024-09-12 |
2026-03-19 |
Astrazeneca Ab |
Treatment of cancer with therapeutic binding molecules
|
|
WO2026078620A1
(en)
|
2024-10-11 |
2026-04-16 |
Medimmune Llc |
Cd22 antibody and drug conjugates and uses thereof
|